Product Information
BUMETANIDE 0.5 MG TABLET is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.1288 per EA under NDC 16571067901. Its NADAC has been published 82 times since Mar 12, 2025.
FDA first approved this application on Dec 12, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.5 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
16571067901
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
BUMETANIDEApproval Type
Generic (ANDA)
FDA Application
ANDA212019FDA Approved
12/12/2019
TE Code
AB
On Market Since
6/3/2024
Pharmacological Classes
Price Statistics
The NADAC for BUMETANIDE 0.5 MG TABLET has been published 82 times since Mar 12, 2025, and over the history we have for it it has declined 9.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1288 per EA |
|---|---|
| All-time high | $0.1658 (Jul 16, 2025) |
| All-time low | $0.1250 (Jul 22, 2026) |
| 52-week high | $0.1428 |
| 52-week low | $0.1250 |
| Median price | $0.1356 |
| Average price | $0.1420 |
| Largest weekly change | +13.3% (Mar 19, 2025) |
| Weeks tracked | 82 |
| Tracking since | Mar 12, 2025 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 2% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
bumetanide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Loop Diuretic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BUMETANIDE 0.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for BUMETANIDE 0.5 MG TABLET, manufactured by Rising Pharma Holdings Inc., is $0.1288 per EA (NDC 16571067901), effective Sep 30, 2026.
How has the price of BUMETANIDE 0.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for BUMETANIDE 0.5 MG TABLET has declined 9.6%. It has been tracked across 82 weekly CMS publications since Mar 12, 2025.
What are the highest and lowest recorded NADAC prices for BUMETANIDE 0.5 MG TABLET?
Since Mar 12, 2025, the NADAC for BUMETANIDE 0.5 MG TABLET has ranged from a low of $0.1250 (Jul 22, 2026) to a high of $0.1658 (Jul 16, 2025), with a median of $0.1356 per EA.
Are there cheaper alternatives to BUMETANIDE 0.5 MG TABLET?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, BUMETANIDE 0.5 MG TABLET, is $0.1265 per EA — about 2% below BUMETANIDE 0.5 MG TABLET.
Who manufactures BUMETANIDE 0.5 MG TABLET?
BUMETANIDE 0.5 MG TABLET (NDC 16571067901) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.